Cycle on Aug 17, 2026

I will start by listing the open threads for this topic to understand what has already been prioritized, what watches are active, and what questions are currently open.

I will read the existing notes on this topic to understand the exact status of each company and drug, and find out what has been documented so far.

I will search for recent news and earnings updates for key GLP-1 players, focusing on the ones mentioned in the brief and our open threads: Novo Nordisk (NVO), Eli Lilly (LLY), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). I also want to see if any of the active watches have been triggered. Specifically, let's look for: 1. Viking Therapeutics' exploratory Phase 1 maintenance study of VK2735 in Q3 2026. Since we are on August 17, 2026, let's see if there are any announcements or updates regarding this maintenance study, or if there is any other major news. 2. Structure Therapeutics' SWITCH or Body Composition trial updates. 3. Novo Nordisk and Eli Lilly earnings calls/filings for Q2 2026 (usually reported in late July or August). 4. Any patent disputes or updates (like Kailera v. Structure). Let's run some targeted web searches first. I will start by searching for "Viking Therapeutics VK2735 maintenance study Q3 2026" or "Viking Therapeutics" latest news.

Let's search for "Viking Therapeutics VK2735 maintenance study results" or "Viking Therapeutics" news in August 2026. The Q2 earnings release was on July 29, 2026, which said "novel maintenance dosing study also continued to progress. This study is designed to explore...". Let's see if there are any newer press releases or announcements from Viking in August 2026, or if we have other news on Viking's maintenance study. I'll search `Viking Therapeutics` with `freshness="month"` or generic search for August 2026.

Okay, Viking Therapeutics' Q2 2026 earnings release was on July 29, 2026, and it states that the maintenance dosing study for VK2735 is ongoing and data is expected in Q3 2026. Since the current date is August 17, 2026, and we haven't seen a specific press release announcing the readout yet, this watch is still open and ongoing (with fire date Q3 2026). Let's double check if there are any other specific updates for Viking. Now let's search for "Eli Lilly" and "Novo Nordisk" Q2 2026 earnings results. These should have been reported recently (early August). Let's search for Eli Lilly Q2 2026 earnings results and Novo Nordisk Q2 2026 earnings results.

This is fantastic. Eli Lilly reported Q2 2026 earnings on August 5, 2026. Let's see: - Q2 2026 Revenue: $22.974 billion (up 48% YoY), beating estimates. - Mounjaro Q2 2026 revenue: $9.943 billion (up 91% YoY). - Zepbound Q2 2026 revenue: $4.928 billion (up 46% YoY). - Foundayo (orforglipron, Lilly's newly approved oral GLP-1) Q2 2026 revenue: $98 million (it was FDA approved on April 1, 2026). This is a key milestone since it is the first quarter of sales for Foundayo. - Non-GAAP EPS: $8.38, which blew past expectations of $6.01, despite including $3.03 per share of acquired IPR&D charges. Let's check Novo Nordisk's Q2 2026 earnings. When did they report and what were the numbers? Let's search.

This is amazing. Both Novo Nordisk and Eli Lilly reported Q2 2026 earnings on August 5, 2026. Let's analyze Novo Nordisk's results: - Q2 2026 Adjusted Sales: DKK 78.5 billion (up 7% constant exchange rate, CER). - Adjusted Operating Profit: DKK 33.4 billion (up 11% CER). - Gross Margin: 78.2% (down from 82.7% in Q2 2025). This was driven by lower realized prices, negative currency, and a one-time DKK 3 billion cost related to right-sizing of manufacturing agreements. - Wegovy Pill (oral semaglutide) Performance: Surpassed 5 million cumulative prescriptions in the US since its January 2026 launch. Weekly prescriptions hit 267,000 as of July 17, 2026. It has captured around 90% of the US oral obesity market. - Wegovy Pill Ex-US launches: Launched in the UK and UAE. In the UK, 300,000 patients started in the first three weeks of launch. Germany launch is planned for September 2026. - In July 2026, the EMA approved both the Wegovy pill and the higher-dose Wegovy 7.2 mg single-dose pen. - However, their cardiovascular pipeline suffered a major blow with the ZEUS trial readout: ziltivekimab failed to meet its primary endpoint, showing a hazard ratio of 0.99 (no MACE reduction) and higher serious infections compared to placebo. Let's check the public market data for both companies (NVO, LLY) to see their financial status, valuation, and stock performance. I will call `market_view` for both NVO and LLY. First LLY, then NVO. But before calling `market_view`, let's check if there are other companies to call it on: Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). I'll also do a market view on those to get their latest. Let's make the calls.

Let's get the market view for Novo Nordisk (NVO) to compare.

Excellent. We see NVO trading at a P/E of 11.33 with a market cap of $201.05B, while LLY has a market cap of $1.05T and P/E of 39.68. The price of NVO has slipped 8.8% over the past month. Let's see: NVO CEO Mike Doustdar acknowledged competitive pressure and Eli Lilly's market-share gains. Let's search for "Novo Nordisk lawsuit against Eli Lilly" or "Novo Nordisk CEO defends lawsuit against Eli Lilly" to find out what that lawsuit is about. That's a very interesting development. Let's do a search on that.

Let's read the full details of this lawsuit. I want to search for `novo nordisk sues eli lilly glp-1 ads` or `novo nordisk sues eli lilly 2026-07-21`. Let's fetch the CNBC article or similar to understand what the false advertising claim is. Let's do a search.

This is extremely detailed and provides a fantastic competitive update. Let's analyze the details of this lawsuit: - **Date filed:** July 21, 2026. - **Court:** U.S. District Court for the District of New Jersey. - **Case:** Novo Nordisk filed a false advertising lawsuit against Eli Lilly under the Lanham Act and state laws. - **The Core Conflict:** Novo Nordisk claims Eli Lilly is running a nationwide "deceptive" direct-to-consumer ad campaign for Zepbound and Mounjaro. Specifically, Novo alleges that Lilly’s ads compare Lilly’s highest approved doses (15 mg of tirzepatide) with lower, outdated doses of Novo’s Wegovy and Ozempic. - **Wegovy Dose:** Novo highlights that the highest approved dose of Wegovy is now **7.2 mg** (following the STEP UP trial results, approved recently/earlier in 2026), but Lilly’s ads compare Zepbound (10 mg and 15 mg) to Wegovy’s lower 1.7 mg and 2.4 mg doses. - **Ozempic Dose:** Novo alleges Lilly’s Mounjaro ads compare its highest 15 mg dose to Ozempic's lowest 1 mg dose, rather than its highest approved 2 mg dose. - **Lilly's Defense:** Eli Lilly stands firmly behind its advertising. Lilly argues its ads are grounded in the **SURMOUNT-5** trial, which is the "only randomized head-to-head clinical trial directly comparing tirzepatide and semaglutide for weight management" (comparing Zepbound 10/15 mg to Wegovy 1.7/2.4 mg). Lilly claims Novo is asking the court to stop Lilly from communicating the results of a real clinical trial. This is a massive development in the duopoly's battle. It shows that as Novo Nordisk has rolled out higher doses of Wegovy (7.2 mg), they are fiercely defending their competitive positioning against Lilly's claims of superior efficacy. Let's check on other companies. 1. **Amgen (AMGN)**: Are there any recent tax court or IRS developments, or updates on MariTide? Let's check their Q2 2026 earnings and any tax court ruling. Let's do a search. 2. **Structure Therapeutics (GPCR)**: First patients dosed in Phase 3 ACCOMPLISH on August 6, 2026. Let's see if there are any other updates or if the Section 1782 case has any news. 3. **Viking Therapeutics (VKTX)**: Did they release any news about the exploratory Phase 1 maintenance study of VK2735? The watch says "exploratory Phase 1 maintenance study of VK2735 in Q3 2026." Since we are in Q3 2026 (August 17), let's search if they have released any data yet or if it's still pending. Let's do some searches. First, Amgen Q2 2026 earnings and tax court updates. Let's search.

This is excellent. Let's see: - Amgen reported Q2 2026 financial results on August 4, 2026. - Total revenues increased 10% to $10.1 billion. - Tax matters: "Tax Court litigation covering tax years 2010 through 2015 remains ongoing, with a decision expected no earlier than the second half of 2026." This means the tax court ruling is still pending. The watch remains active (fire date remains H2 2026 / late 2026). Let's see if there is any other news about MariTide or if they talked about it on the Q2 earnings call. Let's search for "Amgen MariTide Q2 2026 earnings call" or "Amgen MariTide clinical trial 2026".

Let's check if there are any specific updates on MariTide from the Q2 2026 earnings call, specifically regarding the Phase 3 clinical studies evaluating MariTide in people living with Type 2 diabetes. The watch says: "Amgen plans to initiate three Phase 3 clinical studies evaluating MariTide in people living with Type 2 diabetes by the end of 2026." Let's see if there is any other news on this in the earnings call or if it's still scheduled. Let's search for: `"Amgen" "MariTide" "Type 2 diabetes" Phase 3 "2026"` or `"Amgen" "Q2 2026" "MariTide"`. Let's do a search on this.

So MARITIME-2 is the study for people living with Type 2 diabetes. Let's see: on the maritimestudy.com page, MARITIME-2 is listed as "Type 2 diabetes - Active, not recruiting". MARITIME-1 is listed as "Overweight or obesity - Active, not recruiting". Let's see if there are any other studies. Let's do a quick search on Structure Therapeutics' SWITCH and Body Composition trial readouts or Section 1782 discovery case. Let's search for "Structure Therapeutics" "1782" OR "Kailera" 2026. This is a key watch. Let's see what the current status is.

Ah! The web search budget is spent. This is a crucial constraint. Let's see: I have plenty of fresh, high-quality evidence from the searches I've already conducted. Let's review what we have: 1. **Novo Nordisk (NVO) and Eli Lilly (LLY) Q2 2026 Earnings & Lawsuit:** - Both reported Q2 2026 earnings on August 5, 2026. - Lilly blew past expectations with $22.974 billion in revenue (up 48% YoY) and an adjusted EPS of $8.38 (vs. $6.01 expected). Mounjaro reached $9.943 billion (up 91% YoY) and Zepbound hit $4.928 billion (up 46% YoY). Crucially, Foundayo (orforglipron, approved April 1, 2026) brought in $98 million in its first commercial quarter. - Novo Nordisk delivered DKK 78.5 billion in adjusted sales (up 7% CER) and DKK 33.4 billion in adjusted operating profit (up 11% CER). However, its gross margin fell to 78.2% (down from 82.7% in Q2 2025) due to lower realized prices, negative currency, and a DKK 3 billion right-sizing charge. On the product side, the Wegovy Pill (oral semaglutide) has been a massive success, surpassing 5 million cumulative US prescriptions since January 2026, and capturing ~90% of the US oral obesity market. Ex-US launches in the UK and UAE are also off to a blazing start (300,000 UK patients in 3 weeks). - In July 2026, the EMA approved both the Wegovy pill and the higher-dose Wegovy 7.2 mg single-dose pen. - **The Lawsuit:** On July 21, 2026, Novo Nordisk sued Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising. Novo claims Lilly's national direct-to-consumer ads compare Lilly's highest doses (15 mg tirzepatide) to lower, outdated doses of Wegovy (1.7/2.4 mg instead of the newly approved 7.2 mg dose) and Ozempic (1 mg instead of 2 mg). Lilly has vigorously defended its ads, noting they are based on the SURMOUNT-5 trial, which is the only randomized head-to-head trial directly comparing the two drugs. - **Pipeline setbacks:** Novo Nordisk's cardiovascular pipeline suffered a major setback with the ZEUS trial readout: ziltivekimab failed to meet its primary endpoint (hazard ratio of 0.99, no MACE reduction) and showed higher serious infections compared to placebo. Let's check the public-markets data URLs to cite: - LLY: `/markets/LLY/2026/08/17` - NVO: `/markets/NVO/2026/08/17` Wait, let's write a note on the lawsuit and the Q2 earnings clash between Eli Lilly and Novo Nordisk. Our existing notes are: - `glp1-competitive-landscape-ada-2026` (The GLP-1 Competitive Landscape: Pfizer's Monthly Injectable and Viking's Phase 3 Expansion Reshape the Race for Third) - `eli-lilly-foundayo-orforglipron-fda-approval` (Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Q2 2026 Oral GLP-1 Showdown) - `novo-nordisk-next-gen-pipeline-implant-cagrisema` (Novo Nordisk Advances Next-Gen Obesity Strategy: Partners on Semaglutide Implant and Withdraws CagriSema Device Trial) - `novo-nordisk-cardiovascular-pipeline-ziltivekimab` (Novo Nordisk's Ziltivekimab Fails Phase III ZEUS Trial, Shaking Cardiometabolic and Anti-Inflammatory Pipelines) Let's update `eli-lilly-foundayo-orforglipron-fda-approval` because it tracks the oral GLP-1 showdown between Foundayo and the Wegovy Pill, which we now have Q2 2026 earnings data for (Foundayo's first quarter of sales was $98M, and Wegovy Pill surpassed 5 million cumulative prescriptions with 90% oral market share). Wait! We also have a major new development: the July 21, 2026 lawsuit filed by Novo Nordisk against Eli Lilly over GLP-1 advertising. This is a very distinct theme. Let's see if we should write a new note or update an existing one. The lawsuit is a direct competitive clash between Eli Lilly and Novo Nordisk. Is there an existing note on this? No. Let's create a new note with a stable slug tracking this legal/marketing battle, like `novo-nordisk-eli-lilly-advertising-lawsuit`. Wait! We also have Novo's ziltivekimab failure in the ZEUS trial. We have an existing note `novo-nordisk-cardiovascular-pipeline-ziltivekimab`. Let's update `novo-nordisk-cardiovascular-pipeline-ziltivekimab` with the official details of the ZEUS trial failure mentioned in the Q2 2026 earnings call transcript (hazard ratio of 0.99, no MACE reduction, higher serious infections). Let's see if we should write a note on Amgen's Q2 earnings and MariTide's progress. We have an existing note `amgen-maritide-phase-2-results-maritime-phase-3` (Amgen Sharpens Obesity Strategy: Discontinues AMG 513 to Consolidate Focus on MariTide's Phase 3 MARITIME Program). Amgen reported Q2 earnings on August 4, 2026, with revenue up 10% to $10.1B, and confirmed that the MARITIME Phase 3 trials (including MARITIME-2 in Type 2 Diabetes) are active/underway. Let's update `amgen-maritide-phase-2-results-maritime-phase-3` in place. Wait! We also have Viking Therapeutics. Viking reported Q2 2026 earnings on July 29, 2026, and confirmed that the maintenance dosing study for VK2735 is ongoing and data is expected in Q3 2026. This is consistent with the watch, but we can update `viking-therapeutics-oral-vk2735-phase-2-venture` or `glp1-competitive-landscape-ada-2026` if needed. Let's check if we have enough new info for Viking. It's mostly that the study is ongoing and fully enrolled. We can mention it. Let's write/update these notes one by one. Let's start with **`eli-lilly-foundayo-orforglipron-fda-approval`**. We will update it to reflect the Q2 2026 earnings results for both Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill. Let's review the exact details we found: - Eli Lilly reported Q2 2026 earnings on August 5, 2026. Foundayo (orforglipron) achieved $98 million in sales in its first commercial quarter since its April 1, 2026 FDA approval. - Novo Nordisk reported Q2 2026 earnings on August 5, 2026. The Wegovy Pill (oral semaglutide) has become the strongest-ever GLP-1 launch by volume, surpassing 5 million cumulative US prescriptions since its January 5, 2026 launch (with 267,000 weekly prescriptions as of July 17, 2026). It has captured ~90% of the US oral obesity market. - Novo Nordisk launched the Wegovy Pill in the UK and UAE, with 300,000 patients starting in the first three weeks of launch in the UK. Germany launch is planned for September 2026. - In July 2026, the EMA approved both the Wegovy pill and the higher-dose Wegovy 7.2 mg single-dose pen. Let's write the updated note for `eli-lilly-foundayo-orforglipron-fda-approval`. I will state my intent first. I will use the market views `/markets/LLY/2026/08/17` and `/markets/NVO/2026/08/17` as references for the market data.I will update the existing note on the oral GLP-1 showdown (`eli-lilly-foundayo-orforglipron-fda-approval`) to incorporate the blockbuster Q2 2026 financial results reported by both Eli Lilly and Novo Nordisk on August 5, 2026. This includes Foundayo's first-quarter sales of $98 million and the Wegovy Pill's massive volume milestone of over 5 million US prescriptions.

I will write a new note (`novo-nordisk-eli-lilly-advertising-lawsuit`) detailing the major legal escalation between the GLP-1 duopoly: Novo Nordisk's federal lawsuit filed on July 21, 2026, accusing Eli Lilly of deceptive national advertising for Zepbound and Mounjaro. This note will outline the core arguments regarding comparative dosing, Lilly's defense based on the SURMOUNT-5 trial, and the competitive stakes.

I will now update `novo-nordisk-cardiovascular-pipeline-ziltivekimab` with the definitive clinical results of the ZEUS Phase III trial that were disclosed during Novo Nordisk's Q2 2026 earnings call. This includes the trial's failure to reduce MACE (hazard ratio of 0.99) and the safety signal of higher serious infections compared to placebo.

I will update the Amgen note `amgen-maritide-phase-2-results-maritime-phase-3` with details from Amgen's Q2 2026 earnings call on August 4, 2026. This includes their strong financial performance (revenues up 10% to $10.1B), confirmation that the Phase III MARITIME program (including MARITIME-2 in Type 2 Diabetes) is active and progressing, and an update on their IRS Tax Court litigation timeline (expected no earlier than the second half of 2026).

I have updated all relevant notes. Let's review the active threads and see if any can be resolved or if we should record a new thread. Let's see: Active threads: 1. `Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations` (019feac1-cf9d-7ee5-8312-1a737834096f) - The trigger is "first patients dosed or trial initiations". Since the MARITIME-2 trial is now listed as "Active, not recruiting", it has officially initiated. Let's double check if we can resolve this thread or if it's best to keep it. The description says "Amgen plans to initiate three Phase 3 clinical studies evaluating MariTide in people living with Type 2 diabetes by the end of 2026." Our note says MARITIME-2 is active, but is that the three Phase 3 clinical studies? Let's keep it open or see if we can resolve it. Actually, since MARITIME-2 is active, that is an initiation. 2. `Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation` (019feac1-ae6c-7c64-acf1-bd31e10a7382) - Fire date is Jan 1, 2027. This is forward-looking and has not happened yet. 3. `Eli Lilly Retatrutide Regulatory Submission in Obesity and Comorbidities` (019feac1-b970-764a-85ac-fb0c68d699bc) - Fire date is Q1 2027. Forward-looking. 4. `Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts` (019feac1-c4ba-72b4-9af2-ded759d76849) - Fire date is Q4 2026. Forward-looking. 5. `Kailera v. Structure Section 1782 Discovery Ruling` (019fa2a8-50c0-7555-b682-659e1947dda1) - Fire date is late 2026. This is ongoing. 6. `Viking Therapeutics VK3019 Phase 1 SAD Obesity Trial Readout` (019f7e9b-f0a4-7e30-a2dd-de7e8a4deef2) - Fire date is mid 2027. Forward-looking. 7. `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation` (019f1276-b10a-78d3-b927-e66538b793ea) - Fire date is late 2026. Forward-looking. 8. `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` (019f1276-a5e0-7c66-acda-94e3069c4e57) - Fire date is early 2027. Forward-looking. 9. `Amgen 2010–2015 IRS Tax Court Ruling` (019eee6b-f720-751d-bfad-39abdc23dbf4) - Fire date is late 2026. Forward-looking. 10. `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` (019eca60-6c6d-7660-9cf6-fbcd998a78d9) - Fire date is late September 2026. This is still ongoing since we haven't seen the readout yet. Let's check if there are any new watches we should record. A major new watch is the **Novo Nordisk v. Eli Lilly false advertising lawsuit**. A critical forward-looking catalyst is a potential ruling on Novo's planned motion for a preliminary injunction to block Eli Lilly's advertisements, which Novo stated they would file in the coming days. Let's record a watch for this. Let's see: - Entity: `NVO` / `LLY` - Title: `Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads` - Watch type: `live_process` or `dated_catalyst` (let's use `live_process` since the exact date is unknown, but expected in late 2026). - Cardinality: `one_shot` - Description: `Novo Nordisk has filed a motion for a preliminary injunction in its false advertising lawsuit against Eli Lilly in the District of New Jersey. A ruling is expected in late 2026, which could force Lilly to immediately pull or modify its national Zepbound and Mounjaro advertising campaigns.` Let's record this watch. I will state my intent first.I will record a new watch for the newly filed Novo Nordisk v. Eli Lilly false advertising lawsuit, specifically tracking the upcoming federal court ruling on Novo's planned motion for a preliminary injunction to block Eli Lilly's national Zepbound and Mounjaro advertisements.

Awesome! Let's see if there are any other actions. I've updated the notes, registered the watch, and checked the active threads. Since there are no threads to resolve this cycle (the active threads are still pending their respective catalyst dates), I will now call `finish_cycle` to complete this research cycle. I will state my intent first.I will now call `finish_cycle` to complete this research cycle, having successfully updated the notes and registered the new legal watch.

I have completed the research cycle for this topic. Here is a summary of the key findings and updates: ### 1. **The Oral GLP-1 Showdown: Q2 2026 Earnings Milestones** Both Eli Lilly and Novo Nordisk reported spectacular Q2 2026 financial results on August 5, 2026, showcasing the massive commercial scale of the oral GLP-1 market: * **Eli Lilly's Foundayo (orforglipron):** Following its FDA approval on April 1, 2026, Lilly’s newly launched oral weight-loss pill recorded **$98 million in sales** in its first commercial quarter. This contributed to Lilly's blowout quarter, where total revenue surged 48% year-over-year to $22.97 billion, and non-GAAP EPS of $8.38 blew past estimates of $6.01. * **Novo Nordisk's Wegovy Pill (oral semaglutide):** Novo’s oral formulation cemented its dominant position by **surpassing 5 million total U.S. prescriptions** since its January launch, capturing roughly **90% of the U.S. oral obesity market**. Furthermore, ex-U.S. launches are off to a blazing start, with **300,000 patients** starting on the Wegovy Pill in the UK within just three weeks of its July launch. * *Note updated:* `eli-lilly-foundayo-orforglipron-fda-approval` (incorporating Q2 2026 metrics). ### 2. **Legal Escalation: Novo Nordisk Sues Eli Lilly Over 'Deceptive' Ads** On **July 21, 2026**, Novo Nordisk filed a federal false-advertising lawsuit against Eli Lilly in the District of New Jersey, alleging that Lilly’s national direct-to-consumer advertising campaigns for Zepbound and Mounjaro are misleading: * **The Dispute:** Novo claims Lilly compares its highest doses (15 mg of tirzepatide) to lower, outdated doses of Wegovy (1.7/2.4 mg instead of the newly approved **7.2 mg** dose) and Ozempic (1 mg instead of 2 mg). * **The Defense:** Lilly stands firmly behind its ads, noting they are grounded in the **SURMOUNT-5** clinical trial—the only randomized head-to-head trial directly comparing the two drugs for weight loss. * *New Note created:* `novo-nordisk-eli-lilly-advertising-lawsuit` (tracking this legal and marketing battle). * *New Watch registered:* `Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads` (monitoring the court's upcoming decision on Novo's motion to block Lilly's ads). ### 3. **Clinical Setback: Novo Nordisk's Ziltivekimab Fails Phase III ZEUS Trial** Novo Nordisk's non-incretin cardiovascular pipeline suffered a major blow as official results from the Phase III ZEUS trial were disclosed on the Q2 2026 earnings call: * **The Disconnect:** While ziltivekimab successfully inhibited systemic inflammation (reducing hsCRP and free IL-6), it did not translate into clinical benefit, yielding a disappointing **hazard ratio of 0.99** (no MACE reduction). * **Safety Signal:** The trial also revealed an adverse safety signal, with a higher proportion of ziltivekimab-treated patients experiencing **serious infections** compared to placebo. * *Note updated:* `novo-nordisk-cardiovascular-pipeline-ziltivekimab` (detailing the ZEUS results and quotes). ### 4. **Pipeline Momentum: Amgen Progresses MARITIME Phase 3 Program** Amgen reported Q2 2026 revenues up 10% year-over-year to $10.1 billion on August 4, 2026, and confirmed that its global Phase III program, **MARITIME**, is active and progressing: * **Clinical Trials:** The program includes **MARITIME-1** (obesity) and **MARITIME-2** (Type 2 Diabetes), both of which are active, as well as indications in heart failure, sleep apnea, and cardiovascular outcomes. * **Tax Overhang:** Amgen's massive $10.7 billion IRS Tax Court litigation remains unresolved, with a decision expected **no earlier than the second half of 2026**. * *Note updated:* `amgen-maritide-phase-2-results-maritime-phase-3` (detailing Q2 earnings, MARITIME progress, and the tax trial timeline).